Table 2.
Cerebrospinal Fluid (CSF) Biomarker Measures as Predictors of Annual Change in Whole-Brain and Regional Volume or Thickness Measures in Alzheimer Diseasea
CSF Biomarker | P Value | β Estimate | P Value | β Estimate | P Value | β Estimate | P Value | β Estimate |
---|---|---|---|---|---|---|---|---|
Normalized Whole-Brain Volume | Hippocampal Volume | Entorhinal Thickness | Parahippocampal Thickness | |||||
VILIP-1 | .006b | −0.004 | .01b | −95.0 | .001b | −0.093 | .006b | −0.087 |
tau | .005b | −0.003 | .02b | −90.3 | .01b | −0.076 | .01b | −0.076 |
p-tau181 | .006b | −0.003 | .04b | −76.1 | .008b | −0.076 | .03b | −0.064 |
Aβ42 | .17 | 0.002 | .05 | 77.9 | .15 | 0.048 | .71 | 0.012 |
Aβ40 | .19 | −0.001 | .17 | −57.4 | .24 | −0.039 | .79 | −0.009 |
Fusiform Thickness | Posterior Cingulate Thickness | Precuneus Thickness | Pericalcarine Thickness | |||||
VILIP-1 | .04b | −0.056 | .005b | −0.062 | .07 | −0.036 | .28 | 0.007 |
tau | .04b | −0.057 | .04b | −0.049 | .08 | −0.033 | .52 | −0.005 |
p-tau181 | .001b | −0.081 | .002b | −0.069 | .02b | −0.044 | .36 | −0.006 |
Aβ42 | .58 | −0.017 | .38 | −0.023 | .90 | 0.003 | .44 | −0.006 |
Aβ40 | .10 | −0.055 | .09 | −0.051 | .53 | −0.015 | .61 | −0.010 |
Abbreviation: VILIP-1, visinin-like protein 1.
In these analyses, CSF biomarker measures were standardized to z scores and examined as continuous variables. The given β estimate for a CSF biomarker measure reflects the difference in annual change in a volume or thickness measure per standardized biomarker unit. Analyses were adjusted for age, sex, imaging system type, and apolipoprotein E ε4 genotype. Cerebrospinal fluid Aβ40 levels were used as a control.
P < .05.